The following is a summary of “5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response,” published in the March 2025 issue of Journal of the American Academy ...

Medicare will cover chemotherapy for treating cancer. Because doctors administer fluorouracil intravenously (via the veins), coverage falls under Part A or B. Part A covers it during a hospital ...

Engaging in physical activity is a strategy that may enable patients to live longer after their cancer diagnosis and live a length of life that begins to approximate the national norms,” said Justin C ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

US-based Nigerian scientist Charles Izuchukwu Ezekiel has discovered a groundbreaking molecule that could transform prostate ...

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma ...

(HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online in Practical Radiation Oncology, evidence-based recommendations are ...

For most patients, definitive treatment with combined modality therapy is recommended using concurrent 5-fluorouracil or capecitabine plus mitomycin, with cisplatin as a conditional alternative to ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters' model: A regenerative ...